Loading...
Market
What will be Biogen's ranking among biotech companies by market cap at end of 2024?
3
Resolution / Starting Odds
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Market capitalization data from financial platforms like Bloomberg or Yahoo Finance
Story
Biogen Raises Guidance as Leqembi Sales Boost Q3 Earnings, Stock Rises
Oct 31, 2024, 10:38 AM
Biogen Inc. reported stronger-than-expected third-quarter earnings for 2024 and raised its full-year earnings guidance, as cost-cutting measures helped offset declining sales of its multiple sclerosis medications. The company increased its full-year non-GAAP diluted EPS guidance to between $16.10 and $16.60, up from the previous range of $15.75 to $16.25. Biogen's revenue for the quarter was $2.5 billion, with GAAP diluted EPS of $2.66 and non-GAAP diluted EPS of $4.08, surpassing analysts' estimates. Sales of its Alzheimer's drug Leqembi contributed to the positive results, generating global in-market sales of $67 million, including $39 million in the United States. The company's stock rose after the announcement, reflecting investor optimism in Biogen's performance and outlook.
View original story
Similar markets
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Outside Top 50 • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Below Top 3 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%
Top 1 • 25%
Top 2-5 • 25%
Top 6-10 • 25%
Outside top 10 • 25%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Top 3 • 25%
4th to 6th • 25%
7th to 10th • 25%
Outside top 10 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
1st to 3rd • 25%
4th to 6th • 25%
7th to 9th • 25%
10th or lower • 25%